Pre-eclampsia
- PMID: 8754607
Pre-eclampsia
Abstract
PIP: The pregnancy complication characterized by proteinuric hypertension is called preeclampsia. Preeclampsia, an important cause of maternal and perinatal death, has an onset and progression impossible to predict. Termination of pregnancy is the only cure of preeclampsia. It is indicated when the fetus can survive outside the uterus or when the maternal condition deteriorates to such a condition that continuation would bring greater harm to the mother. The etiology of preeclampsia is unknown. Preeclampsia appears to be linked to abnormal trophoblastic implantation. In normal pregnancies, implantation effects changes in the spiral arteries that supply the intervillous space and fibrin-containing trophoblast, and amorphous matrix replace the endothelium and the internal elastic lamina. These changes do not occur or are limited in pre-eclamptic women. There appears to be a familial tendency to preeclampsia. Impaired formation of blocking antibodies to antigenic sites on the placenta increases the risk of pre-eclampsia. Risk factors are primigravidity, short duration of sexual cohabitation before conception, abundance of trophoblastic tissue (e.g., multifetal and molar pregnancies), and underlying vascular disease as in diabetes. Poor placental perfusion may account for the increase in maternal blood pressure. Preeclampsia can lead to eclampsia, cerebral hemorrhage, coagulopathy, and death. Poor utero-placental circulation retards fetal growth and causes fetal distress and maybe even perinatal death. When the diastolic blood pressure is higher than 110 mmHg, pre-eclamptic women should be administered antihypertensive drugs (e.g., methyldopa, beta-blockers, calcium channel blockers, hydralazine, labetatol, or diazoxide) to prevent maternal complications, but these drugs do not improve utero-placental blood flow nor do they prevent proteinuria. Diuretics should not be administered. Proteinuria indicates that the kidneys have been affected. A large randomized trial shows that aspirin does not effectively prevent preeclampsia. Routine calcium supplementation does appear to prevent it and preterm delivery.
Similar articles
-
[Treatment of hypertensive diseases in pregnancy--general recommendations and long-term oral therapy].Z Geburtshilfe Neonatol. 1997 Nov-Dec;201(6):240-6. Z Geburtshilfe Neonatol. 1997. PMID: 9491543 Review. German.
-
Antihypertensive drugs in pregnancy.Clin Perinatol. 1985 Oct;12(3):521-38. Clin Perinatol. 1985. PMID: 2865023 Review.
-
[Hypertension and pregnancy. Diagnosis, physiopathology and treatment].Schweiz Med Wochenschr. 1995 Nov 25;125(47):2273-98. Schweiz Med Wochenschr. 1995. PMID: 8539576 Review. French.
-
The global impact of pre-eclampsia and eclampsia.Semin Perinatol. 2009 Jun;33(3):130-7. doi: 10.1053/j.semperi.2009.02.010. Semin Perinatol. 2009. PMID: 19464502 Review.
-
[Latest developments: management and treatment of preeclampsia].J Gynecol Obstet Biol Reprod (Paris). 2008 Feb;37(1):5-15. doi: 10.1016/j.jgyn.2007.09.008. Epub 2007 Nov 28. J Gynecol Obstet Biol Reprod (Paris). 2008. PMID: 18054175 Review. French.